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ABSTRACT
BACKGROUND
Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the 
efficacy of eltrombopag for increasing platelet counts and reducing the need for 
platelet transfusions in patients with thrombocytopenia and chronic liver disease 
who are undergoing an elective invasive procedure.
METHODS
We randomly assigned 292 patients with chronic liver disease of diverse causes and 
platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a 
dose of 75 mg daily, or placebo for 14 days before a planned elective invasive proce-
dure that was performed within 5 days after the last dose. The primary end point 
was the avoidance of a platelet transfusion before, during, and up to 7 days after the 
procedure. A key secondary end point was the occurrence of bleeding (World Health 
Organization [WHO] grade 2 or higher) during this period.
RESULTS
A platelet transfusion was avoided in 104 of 145 patients who received eltrombopag 
(72%) and in 28 of 147 who received placebo (19%) (P<0.001). No significant difference 
between the eltrombopag and placebo groups was observed in bleeding episodes of 
WHO grade 2 or higher, which were reported in 17% and 23% of patients, respec-
tively. Thrombotic events of the portal venous system were observed in 6 patients who 
received eltrombopag, as compared with 1 who received placebo, resulting in the 
early termination of the study. The incidence and severity of other adverse events 
were similar in the eltrombopag and placebo groups.
CONCLUSIONS
Eltrombopag reduced the need for platelet transfusions in patients with chronic 
liver disease who were undergoing elective invasive procedures, but it was associated 
with an increased incidence of portal-vein thrombosis, as compared with placebo. 
(Funded by GlaxoSmithKline; ELEVATE ClinicalTrials.gov number, NCT00678587.)
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Thrombocytopenia is frequently ob-served in patients with chronic liver dis-ease, with studies suggesting that it oc-
curs in up to 76% of patients with cirrhosis.1-3 
The degree of thrombocytopenia is proportional 
to the severity of the liver disease.4,5 Thrombocy-
topenia increases the risk of bleeding during and 
after invasive procedures and may result in the 
cancellation or postponement of elective proce-
dures.6 Platelet transfusions are commonly used 
to reduce the risk of bleeding during a procedure, 
but their short duration of efficacy and the risk of 
transfusion reactions limit their use.7,8 Further-
more, the development of antiplatelet antibodies 
(alloimmunization) can cause refractory throm-
bocytopenia in up to half of patients who receive 
multiple transfusions.9
Eltrombopag is an oral thrombopoietin-recep-
tor agonist approved for use in patients with chron-
ic immune thrombocytopenia. A phase 2 study 
showed that eltrombopag could increase platelet 
counts in patients with thrombocytopenia and 
hepatitis C.10 This article reports the results of 
the Eltrombopag Evaluated for Its Ability to Over-
come Thrombocytopenia and Enable Procedures 
(ELEVATE) study — a double-blind, placebo-con-
trolled trial that evaluated the ability of eltrom-
bopag to increase platelet counts and reduce the 
need for platelet transfusions in patients with 
thrombocytopenia and chronic liver disease who 
were undergoing an elective invasive procedure.
METHODS
PATIENTS
Eligible patients were 18 years of age or older, had 
chronic liver disease and a platelet count of less 
than 50,000 per cubic millimeter, and in the opin-
ion of the investigator, would require a platelet 
transfusion to manage the risk of bleeding before 
undergoing an elective invasive procedure. Addi-
tional eligibility criteria were a Child–Pugh score11 
of 5 to 12 (on a scale from 5 to 15, with higher 
scores indicating more severe liver disease) and a 
score of 6 to 24 on the Model for End-Stage Liver 
Disease criteria12 (on a scale from 6 to 40, with 
higher scores indicating more advanced liver dis-
ease). Patients were excluded if they were preg-
nant or if they had evidence of portal-vein throm-
bosis on abdominal imaging within 3 months after 
study entry (no baseline imaging was required), a 
history of arterial or venous thrombosis with on-
going risk factors for thrombosis, any condition 
associated with World Health Organization (WHO) 
grade 3 or 4 bleeding, a history of abnormal plate-
let aggregation, or an active infection requiring 
systemic antibiotic agents.
STUDY DESIGN
The study was a double-blind, randomized, placebo- 
controlled, phase 3 trial conducted in 13 coun-
tries. Patients were assigned in a 1:1 ratio to a 
study group and were stratified according to the 
bleeding risk associated with the invasive proce-
dure. Patients received either eltrombopag at a dose 
of 75 mg or matched placebo once daily for 14 days 
(Fig. 1S in the Supplementary Appendix, available 
with the full text of this article at NEJM.org). Pa-
tients were assessed after 7 days of treatment (day 
8) and 1 day after receiving the last dose of study 
medication (day 15). Invasive procedures were to 
be performed no more than 5 days after the pa-
tient received the final dose (days 15 to 19). On the 
day of the procedure, patients with a platelet count 
of more than 80,000 per cubic millimeter did not 
receive a platelet transfusion. Patients with a plate-
let count of less than 50,000 per cubic millimeter 
received a platelet transfusion before the proce-
dure, according to local guidelines. Patients with 
a platelet count between 50,000 and 80,000 per 
cubic millimeter received a platelet transfusion at 
the discretion of the investigator or physician per-
forming the procedure and were treated accord-
ing to local guidelines. Assessments were per-
formed on days 7, 14, 21, and 30 of follow-up. 
The study was concluded after the assessment on 
day 30 of follow-up.
An independent data and safety monitoring 
committee was established to review safety data 
during the study. A clinical events committee re-
viewed data from ophthalmic assessments.
STUDY OVERSIGHT
The study protocol, available at NEJM.org, was ap-
proved by the institutional review board or ethics 
committee at each participating center. The study 
was conducted in accordance with the protocol and 
the Declaration of Helsinki, Good Clinical Practice 
guidelines, and local laws and regulations. All pa-
tients provided written informed consent.
The sponsor, GlaxoSmithKline, and the authors 
designed the study, developed the protocol, and 
analyzed the data. All authors had full access to 
the data, contributed to the writing of the manu-
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script, and vouch for the completeness and ac-
curacy of the reported data and analysis and for 
the fidelity of the study to the protocol. Assis-
tance in writing the first draft of the manuscript 
was provided by a professional medical writer 
paid by the sponsor.
The primary efficacy end point was the pro-
portion of patients who did not require a platelet 
transfusion before, during, and up to 7 days after 
the elective invasive procedure. The key secondary 
end point was the proportion of patients with 
bleeding (WHO grade 2 or higher) before, during, 
and up to 7 days after the procedure. Other sec-
ondary end points included the number of plate-
let transfusions administered before, during, and 
up to 30 days after the procedure, assessments of 
platelet counts throughout the study period, and 
assessments related to safety and adverse events.
STATISTICAL ANALYSIS
To estimate the sample size required for analysis 
of the primary end point, we assumed that the 
proportion of patients who would meet the pri-
mary end point would be 20% for placebo and 50% 
for eltrombopag (see the statistical analysis plan, 
included in the protocol). A total of 120 patients 
(60 in each study group) would provide 90% pow-
er to detect a significant treatment effect with 
the use of a two-sided alpha level of 0.05. To es-
timate the sample size required for analysis of 
the key secondary end point, we assumed that 
the proportion of patients in the placebo group 
with bleeding would be 20%.13 Noninferiority 
with respect to the occurrence of bleeding was 
inferred by ensuring that the upper confidence 
limit (corresponding to the two-sided 95% confi-
dence interval) for the between-group difference 
(the rate of bleeding with eltrombopag minus the 
rate with placebo) did not exceed 10 percentage 
points. A total of 500 patients (250 in each study 
group) would provide 80% power to rule out this 
absolute difference of 10 percentage points at a 
one-sided alpha level of 0.025. Therefore, the 
planned sample was 500 patients.
Following a recommendation from the inde-
pendent data and safety monitoring committee to 
suspend recruitment and dosing, owing to an 
increased frequency of thrombotic events in the 
eltrombopag group, the study was terminated by 
GlaxoSmithKline to allow a full analysis of the 
safety and efficacy data. All prespecified efficacy 
end points were assessed on an intention-to-
treat basis. Safety was assessed among all pa-
tients who underwent randomization and re-
ceived at least one dose of study medication.
In subgroup analyses prespecified in the pro-
tocol, the primary end point was analyzed sepa-
rately for randomization strata and subgroups 
defined on the basis of geographic region, sex, 
race, age, Model for End-Stage Liver Disease 
score, Child–Pugh class, and weight.
RESULTS
PATIENTS
From June 2008 through September 2009, a total 
of 292 patients were enrolled and randomly as-
signed to a study group (Fig. 1S in the Supple-
mentary Appendix). Two patients in each group 
withdrew from the study before treatment be-
gan. Of a total of 288 patients, 145 received pla-
cebo and 143 received eltrombopag at a dose of 
75 mg once daily. The baseline demographic and 
clinical characteristics of the study groups were 
similar (Table 1). The median age was 53 years 
(range, 19 to 83); 64% of the patients were men, 
and 61% were white. A total of 252 patients (86%) 
had cirrhosis, with 10% of all patients having 
Child–Pugh class C disease (i.e., a score of 10 or 
higher) at baseline. The cause of chronic liver 
disease was viral in most cases (80%).
A majority of patients in both study groups 
(62% in the eltrombopag group and 56% in the 
placebo group) underwent elective invasive proce-
dures that were in the lowest bleeding-risk cat-
egory (Table 1S in the Supplementary Appendix). 
Overall, 20 patients receiving placebo and 14 re-
ceiving eltrombopag did not undergo an elective 
invasive procedure during the study.
EFFICACY
Treatment with eltrombopag increased platelet 
counts in the majority of patients, whereas the 
counts remained essentially unchanged in the pla-
cebo group (Fig. 1A). On day 1, 94% of patients 
receiving placebo and 92% of those receiving el-
trombopag had platelet counts of less than 
50,000 per cubic millimeter. On day 15, 59% of 
patients treated with eltrombopag had a platelet 
count of more than 80,000 per cubic millimeter, 
as compared with 5% of those receiving placebo. 
Median platelet counts returned to values ap-
proaching baseline counts within 4 weeks after 
the procedure.
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The primary end point was achieved in 72% of 
the patients (104 of 145) in the eltrombopag group, 
as compared with 19% (28 of 147) in the placebo 
group (P<0.001). The proportion of patients with 
a platelet count between 50,000 and 80,000 per 
cubic millimeter who did not receive a platelet 
transfusion was similar in the two groups (14% in 
the eltrombopag group and 12% in the placebo 
group), confirming that the subjective decision to 
administer a platelet transfusion was not influ-
enced by the group assignment and did not in-
fluence the primary analysis. Two patients in the 
eltrombopag group and 3 in the placebo group 
did not receive a platelet transfusion despite hav-
ing a platelet count of less than 50,000 per cubic 
millimeter. The results of the primary analysis 
were also consistent with those of prespecified 
subgroup analyses (Fig. 1B), with clinically mean-
ingful differences observed for most subgroups, 
including patients with advanced liver disease and 
those who underwent invasive procedures with 
the highest bleeding risk.
The quantity of platelets administered to pa-
tients during each transfusion episode was lower 
in patients receiving eltrombopag than in those 
receiving placebo. The median number of trans-
fused platelet units was 3.0 (2.5 units from a single 
donor and 3.0 units from multiple donors) in the 
eltrombopag group, as compared with a median 
of 4.0 platelet units (2.0 units from a single do-
nor and 5.0 units from multiple donors) in the 
placebo group.
The key secondary end point of noninferiority 
with regard to the rate of bleeding episodes (with 
a noninferiority margin of 10 percentage points) 
was met (23% in the placebo group and 17% in the 
eltrombopag group; absolute difference, –6 per-
centage points; 95% confidence interval [CI], 
–15 to 3).
SAFETY
The incidence and severity of adverse events were 
similar in the two groups. The most common 
adverse events, occurring in more than 3% of pa-
tients in either study group, are reported in Table 
2. Those occurring in at least 5% of patients in 
either group were headache, pyrexia, abdominal 
pain, diarrhea, nausea, and hepatic encephalopa-
thy. A complete list of adverse events is provided 
in Table 2S in the Supplementary Appendix. The 
incidence of elevated alanine aminotransferase 
levels was similar in the two study groups (0% in 
the placebo group and 1% in the eltrombopag 
group). A majority of patients who had an adverse 
event (76%) did so after the treatment (more than 
1 day after the last dose of study medication).
Serious adverse events occurred in 19 patients 
receiving eltrombopag (13%) and in 17 receiving 
placebo (12%). The most common serious adverse 
events in both groups (occurring in at least 2 pa-
Table 1. Baseline Demographic and Clinical Characteristics.*
Characteristic
Placebo
(N = 147)
Eltrombopag
(N = 145)
Age — yr
Median 54 52
Range 19–83 19–79
Male sex — no. (%) 92 (63) 96 (66)
Race — no. (%)
White 93 (63) 85 (59)
Asian 52 (35) 55 (38)
Other 2 (1) 5 (3)
Platelet count — ×10−3 per cubic millimeter†
Median 40 40
Range 8–222 12–62
Child–Pugh class — no./total no. (%)‡
A 63/146 (43) 72/145 (50)
B 66/146 (45) 62/145 (43)
C 17/146 (12) 11/145 (8)
MELD score§
Median 12 12
Range 6–25 6–24
Most common cause of chronic liver disease 
— no. (%)¶
Hepatitis C 106 (72) 91 (63)
Hepatitis B 16 (11) 22 (15)
Alcoholic liver disease 11 (7) 10 (7)
* None of the characteristics differed significantly between the two study 
groups; the Wilcoxon two-sample test was used for continuous measures, and 
Fisher’s exact test for categorical measures.
† Seven patients in each study group had a platelet count of 50,000 per cubic 
millimeter or higher on day 1.
‡ Child–Pugh scores11 range from 5 to 15, with higher scores indicating more 
severe disease; a score of 5 or 6 indicates class A disease, 7 to 9 class B, and 
10 or higher class C.
§ Scores for the Model for End-Stage Liver Disease12 (MELD) criteria range 
from 6 to 40, with higher scores indicating more advanced liver disease. One 
patient with a MELD score of 25 was incorrectly enrolled in the study but was 
still included in the analyses. Data on MELD score were missing for 7 patients 
in the placebo group and 10 in the eltrombopag group.
¶ The most common causes of chronic liver disease were those occurring in 
more than 5% of patients. Causes were not mutually exclusive.
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tients in each group) were hepatic encephalopathy 
(in 2% of patients), mesenteric-vein thrombosis 
(in 1%), cataracts (in 1%), encephalopathy (in 1%), 
gastroenteritis (in 1%), rectal hemorrhage (in 1%), 
and sepsis (in 1%). With the exception of throm-
botic events, rates of serious adverse events were 
similar in the study groups. Adverse events lead-
ing to the discontinuation of study medication 
occurred in 3 patients in each group. Five deaths 
occurred: three in the eltrombopag group and two 
in the placebo group. One death in the eltrom-
bopag group (due to sepsis) was possibly related 
to therapy. The other two deaths in this group 
were due to upper gastrointestinal hemorrhage 
and sepsis and to lymphoma. The two deaths in 
the placebo group were attributed to chronic 
liver disease and to gastroenteritis and shock.
Eight patients had 10 thrombotic events: 6 pa-
tients (7 events) in the eltrombopag group and 
2 patients (3 events) in the placebo group (odds 
ratio with eltrombopag, 3.04; 95% CI, 0.62 to 
14.82) (Table 3). Nine of the 10 events involved 
the portal venous system, including all the events 
in patients who received eltrombopag; these pa-
tients presented with symptomatic portal-vein or 
splanchnic-vein thromboses. The remaining pa-
tient, who received placebo, had a myocardial in-
farction. Of the 6 patients in the eltrombopag 
group who had a portal-vein thrombosis, 5 had the 
event when the platelet count was higher than 
200,000 per cubic millimeter (the maximum plate-
let count achieved during the study). An associa-
tion between platelet counts of 200,000 per cubic 
millimeter or higher and an increased risk of 
thrombotic events was identified in a post hoc 
analysis. The median time to onset after the first 
dose of study medication was 21.5 days (range, 
15 to 53). None of the events occurred during 
therapy; the median time to onset after the last 
dose was 8.5 days (range, 1 to 38). Five of the 
Figure 1 (facing page). Median Platelet Counts and 
Results of Subgroup Analyses, According to Study 
Group.
Panel A shows the median platelet count in patients 
receiving eltrombopag at a dose of 75 mg once daily or 
placebo for 14 days. I bars indicate the interquartile 
range. Elective invasive procedures were scheduled to 
be performed no more than 5 days after the final dose 
(days 15 to 19). The maximum median platelet count 
(148,000 per cubic millimeter) occurred 7 days after 
the procedure. Panel B shows the odds ratios for the 
avoidance of platelet transfusion before and up to 7 days 
after the elective procedure, according to subgroup 
(primary end point). The forest plot shows odds ratios 
for subgroups defined on the basis of demographic 
and baseline clinical characteristics. Bleeding-risk cate-
gories 3 and 4 (randomization strata) were combined, 
owing to the small samples in these categories. Scores 
for the Model for End-Stage Liver Disease12 (MELD) 
criteria range from 6 to 40, with higher scores indicat-
ing more advanced liver disease. Data on MELD score 
were missing for 2 patients in the placebo group and  
1 in the eltrombopag group. Child–Pugh scores11 range 
from 5 to 15, with higher scores indicating more severe 
disease; a score of 5 or 6 indicates class A disease, 7 to 
9 class B, and 10 or higher class C. Child–Pugh scores 
were missing for 1 patient in the placebo group. Hori-
zontal bars indicate 95% confidence intervals.
Table 2. Adverse Events Occurring in at Least 3% of Patients in Either Study 
Group.*
Event
Placebo
(N = 145)
Eltrombopag
(N = 143)
no. of patients with event (%)
Any 85 (59) 79 (55)
Headache 6 (4) 11 (8)
Pyrexia 10 (7) 8 (6)
Abdominal pain 7 (5) 7 (5)
Diarrhea 5 (3) 7 (5)
Nausea 7 (5) 7 (5)
International normalized ratio increased 3 (2) 6 (4)
Anemia 1 (1) 5 (3)
Epistaxis 3 (2) 5 (3)
Peripheral edema 3 (2) 5 (3)
Pyuria 1 (1) 5 (3)
Ascites 4 (3) 4 (3)
Portal-vein or splanchnic-vein thrombosis 1 (1) 6 (4)
Vomiting 3 (2) 4 (3)
Cataract 5 (3) 3 (2)
Hepatic encephalopathy 7 (5) 4 (3)
Upper abdominal pain 5 (3) 2 (1)
Urinary tract infection 5 (3) 2 (1)
Hematuria 4 (3) 1 (1)
Dizziness 4 (3) 0
* Patients could have more than one adverse event.
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6 patients treated with eltrombopag who 
had a thrombotic event had the event within 
2 weeks after the last dose of study medica-
tion. None of the 8 patients who had throm-
botic events had received both eltrombopag 
and a platelet transfusion or had had any 
blood-product use recorded. In addition, 
none of the 26 patients who received both 
eltrombopag and a platelet transfusion had 
a thrombotic event. Overall, 5 of the 8 pa-
tients with a thrombotic event had evidence 
of cancer.
DISCUSSION
Thrombocytopenia frequently complicates 
the treatment of patients with chronic liver 
disease who require an invasive procedure as 
part of their routine clinical care. This study 
showed that a 75-mg dose of eltrombopag 
administered once daily for 14 days raised 
platelet counts and significantly reduced the 
proportion of patients requiring a platelet 
transfusion related to an invasive procedure 
— findings that were consistent across im-
portant subgroups such as those defined by 
sex, race, age, and randomization stratum 
(bleeding risk associated with the proce-
dure). Analyses of secondary efficacy end 
points showed that fewer platelet units were 
transfused in the eltrombopag group than in 
the placebo group and that the results in the 
eltrombopag group were noninferior to 
those in the placebo group with regard to 
bleeding.
Perhaps a cardinal clinical question to 
ask is whether there is a need for a platelet-
stimulating growth factor or even platelet 
transfusions in patients with liver disease 
who undergo invasive procedures. In a recent 
study examining the bleeding risk among 
patients with severe thrombocytopenia 
(platelet count, <75,000 per cubic millime-
ter), Giannini et al. found that 31% of the 
patients had bleeding.14 Interestingly, in these 
patients awaiting a liver transplant, the plate-
let count rather than coagulopathy was the 
major determinant of the bleeding risk. In 
our study, 23% of the patients who received 
placebo and a platelet transfusion had 
bleeding of WHO grade 2 or higher. Our 
study also showed the variation in global T
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practice with regard to the use of platelet trans-
fusions for thrombocytopenia, since a substan-
tial number of patients with a platelet count 
between 50,000 and 80,000 per cubic millimeter, 
and even five patients with a platelet count of 
less than 50,000 per cubic millimeter, did not 
receive transfusions. Since there are no globally 
accepted clinical practice guidelines for platelet 
transfusion in patients with chronic liver disease 
who undergo invasive procedures, we did allow 
flexibility in using platelet transfusions for pa-
tients with a platelet count between 50,000 and 
80,000 per cubic millimeter, a level at which the 
risk of bleeding is still unclear.
Doppler ultrasonography of the abdomen was 
not required during the study screening period, so 
it is possible that some of the patients at study 
entry had a subclinical partial portal-vein throm-
bosis or a low flow state, which may have con-
tributed to the development or persistence of 
thromboses during the study. We considered a 
number of hypotheses to help explain the in-
creased risk of portal-vein thrombosis among pa-
tients who received eltrombopag. Patients with 
advanced liver disease, such as cirrhosis, typically 
have one or more risk factors that predispose 
them to thrombotic events, including intra-
abdominal cancers, imbalances of the coagula-
tion system, and portal hypertension with re-
duced portal-vein flow.15-17 Furthermore, other 
studies have suggested that patients who un-
dergo an invasive procedure may be at increased 
risk for portal-vein thromboses,18 which have 
been reported in up to 35% of patients with cir-
rhosis and hepatocellular carcinoma.19
We hypothesized that the combination of a 
sustained increase in the platelet count and an 
associated degree of predisposing injury from 
the procedure could have contributed to the de-
velopment of thromboses. Patients who received 
eltrombopag had a sustained increase in the plate-
let count for approximately 2 weeks after the ces-
sation of eltrombopag treatment, whereas patients 
who received placebo and a platelet transfusion 
did not have a sustained increase in the platelet 
count. Thus, an undiagnosed nonocclusive portal-
vein thrombosis could have acted as a nidus of 
clotting activity for the relatively large pool of 
available platelets generated by eltrombopag. If 
there was also local inflammation or vascular 
endothelial injury, the risk of thrombosis would 
be even higher. Interestingly, four of the six pa-
tients receiving eltrombopag who had a throm-
bus underwent procedures that involved the 
splanchnic circulation, such as radiofrequency ab-
lation, transarterial chemoembolization, or vari-
ceal ligation.
Another post hoc analysis identified an as-
sociation between the maximum platelet counts 
measured in the study and thrombotic events: 
patients who had a platelet count of 200,000 per 
cubic millimeter or higher were at increased risk 
for thrombotic events. This association poten-
tially allows for the development of strategies to 
mitigate the risk of thrombotic events in this 
population. Changes in dosing (a decreased dose, 
less-frequent dosing, or a shorter duration of dos-
ing) could be used to minimize the proportion 
of patients who have a platelet count of 200,000 
per cubic millimeter or higher, while maintain-
ing a platelet count that is sufficiently high for the 
patient to undergo an elective invasive procedure 
without having substantial bleeding or requiring 
a platelet transfusion.
In conclusion, treatment with eltrombopag at 
a dose of 75 mg once daily for 14 days reduced 
the need for platelet transfusions in patients with 
chronic liver disease and thrombocytopenia who 
were undergoing elective invasive procedures. 
Platelet counts were increased during treatment 
with eltrombopag and for up to 2 weeks after treat-
ment. However, an increased risk of portal-vein 
thrombosis was observed among patients receiv-
ing eltrombopag. Further exploration of eltrom-
bopag therapy is required, including better iden-
tification of risk factors for the development of 
thrombosis, dose optimization, and careful patient 
selection. Until such studies have been conduct-
ed, eltrombopag is not recommended as an al-
ternative to platelet transfusion in patients with 
chronic liver disease and thrombocytopenia who 
are undergoing an elective invasive pro cedure.
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